Luxiq Patent Expiration

Luxiq is a drug owned by Norvium Bioscience Llc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 24, 2017. Details of Luxiq's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7078058 Corticosteroid-containing pharmaceutical composition
May, 2017

(7 years ago)

Expired
US6126920 Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition
Mar, 2016

(8 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Luxiq's patents.

Given below is the list of recent legal activities going on the following patents of Luxiq.

Activity Date Patent Number
Patent litigations
Expire Patent 13 Aug, 2018 US7078058
Maintenance Fee Reminder Mailed 26 Feb, 2018 US7078058
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 13 Apr, 2010 US7078058
Correspondence Address Change 11 Sep, 2009 US7078058
Correspondence Address Change 02 Jul, 2007 US7078058
Change in Power of Attorney (May Include Associate POA) 14 Mar, 2007 US7078058
Correspondence Address Change 14 Mar, 2007 US7078058
Recordation of Patent Grant Mailed 18 Jul, 2006 US7078058
Patent Issue Date Used in PTA Calculation 18 Jul, 2006 US7078058
Issue Notification Mailed 28 Jun, 2006 US7078058

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Luxiq is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Luxiq's family patents as well as insights into ongoing legal events on those patents.

Luxiq's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Luxiq's generic launch date based on the expiry of its last outstanding patent is estimated to be May 24, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Luxiq Generics:

Betamethasone Valerate is the generic name for the brand Luxiq. 11 different companies have already filed for the generic of Luxiq, with Pharmafair having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Luxiq's generic

How can I launch a generic of Luxiq before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Luxiq's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Luxiq's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Luxiq -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
0.0012 10 Aug, 2007 1 26 Nov, 2012 24 May, 2017 Deferred

Alternative Brands for Luxiq

Luxiq which is used for treating skin diseases with corticosteroid-containing pharmaceutical compositions., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Norvium Bioscience
Olux Used for treating skin diseases using a corticosteroid-containing pharmaceutical composition.





About Luxiq

Luxiq is a drug owned by Norvium Bioscience Llc. It is used for treating skin diseases with corticosteroid-containing pharmaceutical compositions. Luxiq uses Betamethasone Valerate as an active ingredient. Luxiq was launched by Norvium Bioscience in 1999.

Approval Date:

Luxiq was approved by FDA for market use on 28 February, 1999.

Active Ingredient:

Luxiq uses Betamethasone Valerate as the active ingredient. Check out other Drugs and Companies using Betamethasone Valerate ingredient

Treatment:

Luxiq is used for treating skin diseases with corticosteroid-containing pharmaceutical compositions.

Dosage:

Luxiq is available in aerosol, foam form for topical use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.12% AEROSOL, FOAM Discontinued TOPICAL